journal
MENU ▼
Read by QxMD icon Read
search

Neuro-oncology

journal
https://www.readbyqxmd.com/read/28096493/combining-standard-clinical-blood-values-for-improving-survival-prediction-in-patients-with-newly-diagnosed-brain-metastases-development-and-validation-of-the-labbm-score
#1
Anna S Berghoff, Fabian Wolpert, Tim Holland-Letz, Romina Koller, Georg Widhalm, Brigitte Gatterbauer, Karin Dieckmann, Peter Birner, Rupert Bartsch, Christoph C Zielinski, Michael Weller, Matthias Preusser
BACKGROUND: We aimed to investigate the potential of standard hematologic and serum biochemical parameters to provide an independent and substantial contribution to the prediction of survival in patients with newly diagnosed brain metastases (BM). METHODS: Hemoglobin, white blood cell count, platelet count, serum albumin, creatinine, lactate dehydrogenase (LDH), and C-reactive protein (CRP) were assessed at diagnosis of BM in a discovery cohort of 1200 cancer patients...
January 17, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28082416/a-brain-penetrant-raf-dimer-antagonist-for-the-noncanonical-braf-oncoprotein-of-pediatric-low-grade-astrocytomas
#2
Yu Sun, John A Alberta, Catherine Pilarz, David Calligaris, Emily J Chadwick, Shakti H Ramkissoon, Lori A Ramkissoon, Veronica Matia Garcia, Emanuele Mazzola, Liliana Goumnerova, Michael Kane, Zhan Yao, Mark W Kieran, Keith L Ligon, William C Hahn, Levi A Garraway, Neal Rosen, Nathanael S Gray, Nathalie Y Agar, Sara J Buhrlage, Rosalind A Segal, Charles D Stiles
BACKGROUND: Activating mutations or structural rearrangements in BRAF are identified in roughly 75% of all pediatric low-grade astrocytomas (PLGAs). However, first-generation RAF inhibitors approved for adult melanoma have poor blood-brain penetrance and are only effective on tumors that express the canonical BRAFV600E oncoprotein, which functions as a monomer. These drugs (type I antagonists that target the "DFG-in" conformation of the kinase) fail to block signaling via KIAA1549:BRAF, a truncation/fusion BRAF oncoprotein which functions as a dimer and is found in the most common form of PLGA...
January 12, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28082415/smo-mutation-status-defines-a-distinct-and-frequent-molecular-subgroup-in-olfactory-groove-meningiomas
#3
Julien Boetto, Franck Bielle, Marc Sanson, Matthieu Peyre, Michel Kalamarides
BACKGROUND: Meningiomas are the most common primary intracranial tumors in adults. Identification of SMO and AKT1 mutations in meningiomas has raised the hope for targeted therapies. It would be useful to know the precise frequency of these mutations in anatomical subgroups and clarify their prognostic value. METHODS: We used the Sanger sequencing technique to characterize 79 samples of olfactory groove meningiomas for SMO (L412F and W535L) and AKT1 (E17K) mutations...
January 12, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28062831/glioblastoma-on-a-microfluidic-chip-generating-pseudopalisades-and-enhancing-aggressiveness-through-blood-vessel-obstruction-events
#4
Jose M Ayuso, Rosa Monge, Alicia Martínez-González, María Virumbrales-Muñoz, Guillermo A Llamazares, Javier Berganzo, Aurelio Hernández-Laín, Jorge Santolaria, Manuel Doblaré, Christopher Hubert, Jeremy N Rich, Pilar Sánchez-Gómez, Víctor M Pérez-García, Ignacio Ochoa, Luis J Fernández
BACKGROUND: Glioblastoma (GBM) is one of the most lethal tumor types. Hypercellular regions, named pseudopalisades, are characteristic in these tumors and have been hypothesized to be waves of migrating glioblastoma cells. These "waves" of cells are thought to be induced by oxygen and nutrient depletion caused by tumor-induced blood vessel occlusion. Although the universal presence of these structures in GBM tumors suggests that they may play an instrumental role in GBM's spread and invasion, the recreation of these structures in vitro has remained challenging...
January 6, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28062830/dissecting-inherent-intratumor-heterogeneity-in-patient-derived-glioblastoma-culture-models
#5
Jian Teng, Cintia Carla da Hora, Rami S Kantar, Ichiro Nakano, Hiroaki Wakimoto, Tracy T Batchelor, E Antonio Chiocca, Christian E Badr, Bakhos A Tannous
BACKGROUND: Molecular profile of glioblastoma multiforme (GBM) revealed 4 subtypes, 2 of which, proneural and mesenchymal, have been predominantly observed, with the latter displaying a more aggressive phenotype and increased therapeutic resistance. Single-cell RNA sequencing revealed that multiple subtypes actually reside within the same tumor, suggesting cellular heterogeneity in GBM. Further, plasticity between these 2 subtypes is observed during tumor recurrence and in response to radiation therapy...
January 6, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28053137/activation-of-cecr1-in-m2-like-tams-promotes-paracrine-stimulation-mediated-glial-tumor-progression
#6
Changbin Zhu, Dana Mustafa, Ping-Pin Zheng, Marcel van der Weiden, Andrea Sacchetti, Maarten Brandt, Ihsan Chrifi, Dennie Tempel, Pieter J M Leenen, Dirk Jan Duncker, Caroline Cheng, Johan M Kros
BACKGROUND: The majority of glioma-associated microglia/macrophages have been identified as M2-type macrophages with immune suppressive and tumor supportive action. Recently, the extracellular adenosine deaminase protein Cat Eye Syndrome Critical Region Protein 1 (CECR1) was shown to regulate macrophage maturation. In this study, we investigate the role of CECR1 in the regulation of the glioma-associated macrophage response. METHODS: Expression of CECR1 was assessed in human glioma samples...
January 3, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28040713/the-impact-of-body-mass-index-and-height-on-the-risk-for-glioblastoma-and-other-glioma-subgroups-a-large-prospective-cohort-study
#7
Markus K H Wiedmann, Cathrine Brunborg, Antonio Di Ieva, Kristina Lindemann, Tom B Johannesen, Lars Vatten, Eirik Helseth, John A Zwart
BACKGROUND: Glioma comprises a heterogeneous group of mostly malignant brain tumors, whereof glioblastoma (GBM) represents the largest and most lethal subgroup. Body height and body mass index (BMI) are risk factors for other cancers, but no previous study has examined anthropometric data in relation to different glioma subgroups. METHODS: This prospective cohort study includes 1.8 million Norwegian women and men between ages 14 and 80 years at baseline. Body weight and height were measured, and incident cases of glioma were identified by linkage to the National Cancer Registry...
December 31, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28040712/comment-on-hatzoglou-et-al-dynamic-contrast-enhanced-mri-perfusion-versus-18fdg-pet-ct-in-differentiating-brain-tumor-progression-from-radiation-injury
#8
LETTER
Francesco Cicone, Norbert Galldiks, Giuseppe Minniti, Christian P Filss, Francesco Scopinaro, John O Prior, Nathalie L Albert, Karl-Josef Langen
No abstract text is available yet for this article.
December 31, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28040711/-comment-on-hatzoglou-et-al-dynamic-contrast-enhanced-mri-perfusion-vs-18fdg-pet-ct-in-differentiating-brain-tumor-progression-from-radiation-injury-reply
#9
LETTER
Robert J Young, T Jonathan Yang, Vaios Hatzoglou, Gary Ulaner, Antonio Omuro
No abstract text is available yet for this article.
December 31, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28040710/rest-represses-mir-124-and-mir-203-to-regulate-distinct-oncogenic-properties-of-glioblastoma-stem-cells
#10
Anantha L Marisetty, Sanjay K Singh, Tran N Nguyen, Cristian Coarfa, Bin Liu, Sadhan Majumder
BACKGROUND: Glioblastoma (GBM) is one of the most common, aggressive, and invasive human brain tumors. There are few reliable mechanism-based therapeutic approaches for GBM patients. The transcriptional repressor RE1 silencing transcriptional factor (REST) regulates the oncogenic properties of a class of GBM stem-like cells (high-REST [HR]-GSCs) in humans. However, it has been unclear whether REST represses specific targets to regulate specific oncogenic functions or represses all targets with overlapping functions in GSCs...
December 31, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28039369/long-term-control-and-partial-remission-after-initial-pseudoprogression-of-glioblastoma-by-anti-pd-1-treatment-with-nivolumab
#11
LETTER
Patrick Roth, Antonios Valavanis, Michael Weller
No abstract text is available yet for this article.
December 29, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28039368/long-term-neurologic-health-and-psychosocial-function-of-adult-survivors-of-childhood-medulloblastoma-pnet-a-report-from-the-childhood-cancer-survivor-study
#12
Allison A King, Kristy Seidel, Chongzhi Di, Wendy M Leisenring, Stephanie Mabry Perkins, Kevin R Krull, Charles A Sklar, Daniel M Green, Gregory T Armstrong, Lonnie K Zeltzer, Elizabeth Wells, Marilyn Stovall, Nicole J Ullrich, Kevin C Oeffinger, Leslie L Robison, Roger J Packer
BACKGROUND: Medulloblastoma is the most common malignant childhood brain tumor, although long-term risks for chronic neurologic health and psychosocial functioning in aging adult survivors are incompletely characterized. METHODS: The Childhood Cancer Survivor Study (CCSS) includes 380 five-year survivors of medulloblastoma/primitive neuroectodermal tumor (PNET; median age at follow-up: 30 y, interquartile range 24-36) and sibling comparison (n = 4031). Cumulative incidence of neurologic health conditions was reported...
December 29, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28039367/efficacy-and-safety-results-of-abt-414-in-combination-with-radiation-and-temozolomide-in-newly-diagnosed-glioblastoma
#13
David A Reardon, Andrew B Lassman, Martin van den Bent, Priya Kumthekar, Ryan Merrell, Andrew M Scott, Lisa Fichtel, Erik P Sulman, Erica Gomez, JuDee Fischer, Ho-Jin Lee, Wijith Munasinghe, Hao Xiong, Helen Mandich, Lisa Roberts-Rapp, Peter Ansell, Kyle D Holen, Hui K Gan
BACKGROUND: The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma. ABT-414 is a first-in-class, tumor-specific antibody-drug conjugate that preferentially targets tumors expressing overactive epidermal growth factor receptor (EGFR). METHODS: In this multicenter phase I study, patients received 0.5-3.2 mg/kg ABT-414 every 2 weeks by intravenous infusion...
December 29, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28039366/the-use-of-o-2-18f-fluoroethyl-l-tyrosine-pet-in-the-diagnosis-of-gliomas-located-in-the-brainstem-and-spinal-cord
#14
Caroline Tscherpel, Veronika Dunkl, Garry Ceccon, Gabriele Stoffels, Natalie Judov, Marion Rapp, Philipp T Meyer, Elena Rota Kops, Johannes Ermert, Gereon R Fink, Nadim J Shah, Karl-Josef Langen, Norbert Galldiks
BACKGROUND: Despite an increasing number of O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) PET studies in supratentorial gliomas, studies regarding the usefulness of (18)F-FET PET in brainstem and spinal cord gliomas to date remain scarce. METHODS: Thirty-six (18)F-FET PET scans were performed in 29 patients with brainstem (n = 29 scans) or spinal cord glioma (n = 7 scans). In 32 of 36 PET scans, a dynamic acquisition was performed. Fifteen scans in 15 patients were performed to assess newly diagnosed lesions, and 21 scans were obtained during follow-up: for diagnosing tumor progression (n = 15 scans in 14 patients) as well as for treatment monitoring (n = 6 scans in 3 patients)...
December 29, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28039365/complete-prevalence-of-malignant-primary-brain-tumors-registry-data-in-the-united-states-compared-with-other-common-cancers-2010
#15
Adah S Zhang, Quinn T Ostrom, Carol Kruchko, Lisa Rogers, David M Peereboom, Jill S Barnholtz-Sloan
BACKGROUND: Complete prevalence proportions illustrate the burden of disease in a population. This study estimates the 2010 complete prevalence of malignant primary brain tumors overall and by Central Brain Tumor Registry of the United States (CBTRUS) histology groups, and compares the brain tumor prevalence estimates to the complete prevalence of other common cancers as determined by the Surveillance, Epidemiology, and End Results Program (SEER) by age at prevalence (2010): children (0-14 y), adolescent and young adult (AYA) (15-39 y), and adult (40+ y)...
December 29, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28039364/leptomeningeal-metastases-a-rano-proposal-for-response-criteria
#16
REVIEW
Marc Chamberlain, Larry Junck, Dieta Brandsma, Riccardo Soffietti, Roberta Rudà, Jeffrey Raizer, Willem Boogerd, Sophie Taillibert, Morris D Groves, Emilie Le Rhun, Julie Walker, Martin van den Bent, Patrick Y Wen, Kurt A Jaeckle
Leptomeningeal metastases (LM) currently lack standardization with respect to response assessment. A Response Assessment in Neuro-Oncology (RANO) working group with expertise in LM developed a consensus proposal for evaluating patients treated for this disease. Three basic elements in assessing response in LM are proposed: a standardized neurological examination, cerebral spinal fluid (CSF) cytology or flow cytometry, and radiographic evaluation. The group recommends that all patients enrolling in clinical trials undergo CSF analysis (cytology in all cancers; flow cytometry in hematologic cancers), complete contrast-enhanced neuraxis MRI, and in instances of planned intra-CSF therapy, radioisotope CSF flow studies...
December 29, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28039363/impaired-health-related-quality-of-life-in-meningioma-patients-a-systematic-review
#17
REVIEW
Amir H Zamanipoor Najafabadi, Marthe C M Peeters, Linda Dirven, Daniel J Lobatto, Justus L Groen, Marieke L D Broekman, Saskia M Peerdeman, Wilo C Peul, Martin J B Taphoorn, Wouter R van Furth
While surgical and radiotherapeutic improvements increased life expectancy of meningioma patients, little is known about these patients' health-related quality of life (HRQoL). Therefore, the objectives of this systematic review were to assess HRQoL in meningioma patients, the methodological quality of the used questionnaires (COSMIN criteria), and the reporting level of patient-reported outcomes (PROs) in the included studies (International Society of Quality of Life Research criteria).Nineteen articles met our inclusion criteria...
December 29, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28039362/defining-the-temporal-course-of-murine-neurofibromatosis-1-optic-gliomagenesis-reveals-a-therapeutic-window-to-attenuate-retinal-dysfunction
#18
Joseph A Toonen, Yu Ma, David H Gutmann
BACKGROUND: Optic gliomas arising in the neurofibromatosis type 1 (NF1) cancer predisposition syndrome cause reduced visual acuity in 30%-50% of affected children. Since human specimens are rare, genetically engineered mouse (GEM) models have been successfully employed for preclinical therapeutic discovery and validation. However, the sequence of cellular and molecular events that culminate in retinal dysfunction and vision loss has not been fully defined relevant to potential neuroprotective treatment strategies...
December 29, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28025387/the-challenge-of-adequate-imaging-surveillance-in-primary-central-nervous-system-lymphoma
#19
EDITORIAL
Uwe Schlegel, Agnieszka Korfel
No abstract text is available yet for this article.
December 26, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/28011926/evaluation-of-age-dependent-treatment-strategies-for-children-and-young-adults-with-pineoblastoma-analysis-of-pooled-european-society-for-paediatric-oncology-siop-e-and-us-head-start-data
#20
Martin Mynarek, Barry Pizer, Christelle Dufour, Dannis van Vuurden, Miklos Garami, Maura Massimino, Jason Fangusaro, Tom Davidson, Maria Joao Gil-da-Costa, Jaroslav Sterba, Martin Benesch, Nicolas Gerber, B Ole Juhnke, Robert Kwiecien, Torsten Pietsch, Marcel Kool, Steve Clifford, David W Ellison, Felice Giangaspero, Pieter Wesseling, Floyd Gilles, Nicholas Gottardo, Jonathan L Finlay, Stefan Rutkowski, Katja von Hoff
BACKGROUND: Pineoblastoma is a rare pineal region brain tumor. Treatment strategies have reflected those for other malignant embryonal brain tumors. PATIENTS AND METHODS: Original prospective treatment and outcome data from international trial groups were pooled. Cox regression models were developed considering treatment elements as time-dependent covariates. RESULTS: Data on 135 patients with pineoblastoma aged 0.01-20.7 (median 4.9) years were analyzed...
December 23, 2016: Neuro-oncology
journal
journal
34661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"